Candidates who see the most clinical benefit tend to share a common profile: above-average visceral fat relative to their overall body composition, often in the context of metabolic syndrome, age-related GH decline, or prior hormonal disruption
Meanwhile, a post-hoc analysis of the STEP 1 and STEP 4 trials showed that semaglutide 2.4 mg was associated with an approximately 60% reduction of the 10-years risk of T2D according to the Cardiometabolic Disease Staging (CMDS) calculator, regardless of patients baseline glycemic status 74
Because peptides can influence core signaling pathways, safety lies in thoughtful dosage, correct timing, and integration with the patients overall health plan
Shennon I, Wilson BC, Behling AH, Portlock T, Haque R, Forrester T, Nelson CA, OSullivan JM